<DOC>
	<DOCNO>NCT02284386</DOCNO>
	<brief_summary>This Phase 4 , multicenter , open-label study design characterize pharmacokinetic ( PK ) profile total bupivacaine approximately 15 adult subject undergoing primary unilateral total knee arthroplasty ( TKA ) bupivacaine hydrochloride ( HCl ) spinal nerve block ( SNB ) EXPAREL local infiltration surgical site .</brief_summary>
	<brief_title>Pharmacokinetics Safety Bupivacaine HCl Spinal Block EXPAREL Local Infiltration Total Knee Arthroplasty</brief_title>
	<detailed_description>On Day 1 , follow epinephrine `` wash '' spinal block syringe , eligible subject receive single 1.6 mL dose bupivacaine HCl 7.5 mg/mL within 2 hour prior surgical procedure spinal block . EXPAREL 266 mg 20 mL ( expand 70 mL preservative-free sterile normal saline total volume 90 mL ) infiltrate surgical site end surgery prior wound closure . There local co-administration two drug . Blood sample bupivacaine PK analysis obtain subject baseline ( prior bupivacaine HCl administration nerve block ) , 15 minute , 30 minute , 1 , 2 , 4 , 8 , 12 , 24 , 48 , 72 hour begin EXPAREL administration , Day 14 .</detailed_description>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>1 . Males females ≥18 year age . 2 . American Society Anesthesiologists ( ASA ) physical status 1 , 2 , 3 . 3 . Scheduled undergo spinal block conjunction unilateral TKA . 4 . Female subject must surgically sterile , least 2 year postmenopausal , use medically acceptable method birth control . Females childbearing potential must document negative blood urine pregnancy test result within 24 hour surgery . 5 . Able provide inform consent , adhere study schedule , complete study assessment . 1 . History hypersensitivity idiosyncratic reaction amidetype local anesthetic opioids . 2 . Contraindication bupivacaine . 3 . Received bupivacaine local anesthetic within 7 day EXPAREL administration . 4 . Currently pregnant , nursing , plan become pregnant study within 1 month EXPAREL administration . 5 . Planned concurrent surgical procedure ( e.g. , bilateral TKA ) . 6 . Body weight &lt; 50 kg ( 110 pound ) body mass index ≥45 kg/m2 . 7 . Received investigational drug within 30 day prior EXPAREL administration , and/or plan administration another investigational product procedure subject 's participation study . 8 . Previous participation EXPAREL study . 9 . Malignancy last 2 year , exception nonmetastatic basal cell squamous cell carcinoma skin localize carcinoma situ cervix . 10 . Current historical evidence clinically significant disease condition , especially cardiovascular neurological condition , opinion Investigator , may increase risk surgery complicate subject 's postsurgical course . 11 . Clinically significant medical psychiatric disease , opinion Investigator , would constitute contraindication participation study , cause inability comply study requirement . In addition , subject ineligible receive EXPAREL meet follow criterion surgery : 12 . Any clinically significant event condition uncover surgery ( e.g. , excessive bleeding , acute sepsis ) might render subject medically unstable complicate subject 's postsurgical course .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Total knee arthroplasty</keyword>
</DOC>